Key Highlights
- GSK (LSE:GSK) told the market on 10 September that Japan's Ministry of Health, Labour and Welfare has approved a prefilled syringe presentation of Shingrix, its recombinant zoster Vaccine for the prevention of shingles. The approval changes neither what the vaccine contains nor who can receive it, only how it reaches the patient.
- A device change is not a growth driver on its own. Whether the prefilled syringe lifts Japanese uptake depends on clinic adoption, local reimbursement arrangements and competing demands on vaccination capacity.
- A device change is not a growth driver on its own.
Japan Clears a Simpler Shingrix
GSK (LSE:GSK) told the market on 10 September that Japan's Ministry of Health, Labour and Welfare has approved a prefilled syringe presentation of Shingrix, its recombinant zoster vaccine for the prevention of shingles. The approval changes neither what the vaccine contains nor who can receive it, only how it reaches the patient.
Until now, Shingrix has been supplied in Japan as two vials, a lyophilised antigen and a liquid adjuvant, which a healthcare professional must reconstitute before administration. The prefilled syringe removes that step. In a country where vaccination is delivered across a very large number of small clinics, the preparation time saved per dose is not a trivial detail.
The existing indications carry over. Shingrix has been approved in Japan since 2018 for adults aged 50 and over, and since 2023 for adults aged 18 and over at increased risk of herpes zoster.
Why the Japanese Market Matters Here
GSK put the public health case alongside the regulatory one. Around 1.1 million people develop shingles in Japan each year. More than 90% of adults carry the varicella-zoster virus dormant in their nervous system, and up to 30% of those who develop shingles go on to experience post-herpetic neuralgia, nerve pain that can persist for weeks or months.
Sanjay Gurunathan, GSK's head of vaccines and infectious diseases research and development, noted that one in three adults globally will develop shingles in their lifetime and that the condition can carry serious and long-lasting complications.
Japan is the third major market to clear the format. The prefilled syringe was approved by the US Food and Drug Administration and launched there in February 2026, and European Commission approval has supported a rollout across Europe during the year.
A Presentation Change With Commercial Logic
Shingrix is a large but maturing franchise, and the second-quarter numbers explain why convenience matters. In results published on 28 July, GSK reported Shingrix sales of £0.9bn for the quarter, growth of 3%, a noticeably slower rate than the wider vaccines division.
That division delivered £2.3bn of sales, up 8%, with the meningitis portfolio growing 21%. Total group sales reached £8.4bn, up 5% at both actual and constant exchange rates. Specialty medicines were the standout at £3.8bn, up 14%, with respiratory at £1.1bn rising 19%, oncology at £0.6bn up 17% and HIV at £2.1bn up 10%. Core operating profit grew 7% and core Earnings Per Share rose 9%.
Management reaffirmed full-year guidance of 3% to 5% turnover growth and 7% to 9% core EPS growth. A Dividend of 17 pence per share was declared for the quarter, with 70 pence expected for the full year, and the £2bn share repurchase programme was completed.
Japan as a Recurring Theme
The Shingrix approval is the second notable Japanese clearance for GSK in under three weeks. On 24 August the company announced the first global approval of Hibsago, bepirovirsen, in Japan as a functional cure for chronic hepatitis B. The same day it confirmed that the US FDA would review Jemperli in rectal cancer.
That sequence sits within a broader push on research and development. GSK has identified seven asset accelerations across 18 indications and now expects more than 20 phase III trial starts during 2026, double its earlier guidance.
What Could Go Wrong
A device change is not a growth driver on its own. Whether the prefilled syringe lifts Japanese uptake depends on clinic adoption, local reimbursement arrangements and competing demands on vaccination capacity. Shingrix also faces the harder structural task of converting first-time recipients in markets where the most motivated cohorts have already been reached.
Beyond vaccines, the usual variables apply: pricing pressure, US policy on drug costs, Patent expiries and clinical readouts that can move either way. Third-quarter results and the first evidence of Japanese uptake are the next markers.






Please wait processing your request...